Colorectal Cancer

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.

The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions.

The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Living with Lynch isn't easy, but it's not all doom and gloom. It's a call to live deliberately.

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

I always wanted to make a difference, but I never expected my biggest impact to come through cancer.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Melissa Ursini discussed her experience with a colorectal cancer diagnosis at age 37, highlighting her insights during Colorectal Cancer Awareness Month.

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care.

Dr. Zachariah H. Foda discusses key colorectal cancer warning signs, the rise in younger diagnoses and more.

After being diagnosed with colon cancer, I learned the life-changing lessons of self-love, stepping out of my comfort zone and embracing positive thinking.

Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.

Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.

Dr. Andreas M. Kaiser explains how a colostomy may preserve a patient’s health and help to avoid colorectal cancer complications.

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer.

Cancer tested my friendships by showing who could stay present through tough conversations, support me emotionally and endure pain together despite the loss.

In patients with residual disease after curative resection of colorectal cancer, Lonsurf showed a numerical improvement in DFS, though not significant.

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated metastatic colorectal cancer.

Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.